---
title: "Abeona Therapeutics Inc. (ABEO.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ABEO.US.md"
symbol: "ABEO.US"
name: "Abeona Therapeutics Inc."
industry: "生物技术"
---

# Abeona Therapeutics Inc. (ABEO.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.abeonatherapeutics.com](https://www.abeonatherapeutics.com) |

## Company Profile

Abeona Therapeutics Inc.是一家临床阶段的生物制药公司，开发用于治疗危及生命疾病的基因和细胞疗法。其主要临床项目是 pz-cel，这是一种自体细胞基因疗法，用于治疗隐性营养不良性大疱性表皮松解症的患者。该公司还开发 ABO-503 用于治疗 X 连锁视网膜裂孔；ABO-504 用于治疗斯塔加特病；以及 ABO-505 用于治疗常染色体显性视神经萎缩。此外，它还通过其 AIM 载体平台项目开发基于 AAV 的基因疗法

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:11.000Z

**Overall: C (0.47)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 127 / 404 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 215.93% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.59 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 271.50M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 400000.00 |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 75.90% | A |
| Profit Margin | 20587.50% | A |
| Gross Margin | 0.00% | E |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% | C |
| Net Profit YoY | 215.93% | A |
| Total Assets YoY | 91.63% | A |
| Net Assets YoY | 274.09% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 0.49% | C |
| OCF YoY | 0.00% | C |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 25.90% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Abeona Therapeutics Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "75.90%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "20587.50%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "215.93%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "91.63%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "274.09%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "0.49%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "25.90%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | 艾伯维 (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 3.30 | 6/605 | 5.05 | 3.59 | 3.34 |
| PB | 1.59 | 145/605 | 7.23 | 2.23 | 1.64 |
| PS (TTM) | 678.75 | 301/605 | 737.00 | 697.71 | 661.13 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-03T05:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 6 | 86% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.01 |
| Highest Target | 28.00 |
| Lowest Target | 14.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ABEO.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ABEO.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ABEO.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.